Top health-care stocks:
Health-care shares were generally higher in pre-market trade on
Halozyme Therapeutics (
) shares declined pre-market Wednesday, after the biopharmaceutical
company said it was informed by the Food and Drug Administration
that a clinical hold has been placed on patient enrollment and
dosing of its PEGPH20 in an ongoing Phase 2 trial evaluating
PEGPH20 in patients with pancreatic cancer.
The clinical hold comes after Halozyme last week said it was
temporarily halting patient enrollment and dosing in the trial,
following a recommendation.
Intuitive Surgical (
) dropped about 9% in
after providing disappointing preliminary guidance on Q1 results
The maker of robotic surgical equipment said Q1 revenue will
fall 24% from a year earlier to $465 million, compared with the
consensus estimate of $536 million as measured by Capital IQ.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.